

PERSISTENCE OF VESICULAR MONOAMINE TRANSPORT 2 INHIBITOR THERAPY FOR TOURETTE SYNDROME AND CHRONIC TIC DISORDERS

Michael Ong, PharmD¹ | Josh DeClercq, MS² | Leena Choi, PhD² | Autumn D. Zuckerman, PharmD, BCPS, AAHVP, CSP³ | Nisha B. Shah, PharmD³ | Kayla Johnson, PharmD, BCPS, BCPP³ | David Isaacs, MD, MPH⁴

¹Lipscomb University College of Pharmacy, ²Department of Biostatistics, Vanderbilt University Medical Center, ³Vanderbilt Specialty Pharmacy, Vanderbilt University Medical Center, ⁴Department of Neurology, Vanderbilt University Medical Center

BACKGROUND

- Tics associated with Tourette's Syndrome are a debilitating condition that may impact an individual's quality of life
- Traditional pharmacological options, including antipsychotics and alpha agonists, have adverse events that may limit their tolerability and efficacy
- Vesicular Monoamine Transport 2 Inhibitors (VMAT2i) have been shown to improve hyperkinetic symptoms of tardive dyskinesia and Huntington's disease chorea¹
- Efficacy data for VMAT2i use for tics associated with Tourette's Syndrome remains inconclusive^{2,3}

PRIMARY OBJECTIVE

Assess the persistence rate of newly initiated VMAT2i therapy (deutetrabenazine, tetrabenazine, and valbenazine) for chronic tic management at 12 months post-initiation

METHODS

Setting	<ul style="list-style-type: none"> Academic medical center with an integrated specialty pharmacy
Design	<ul style="list-style-type: none"> Retrospective cohort study January 1, 2018 to December 31, 2020
Sample	<ul style="list-style-type: none"> Inclusion: <ul style="list-style-type: none"> Age ≥ 18 years old Diagnosis of a chronic tic disorder VMAT2i prescribed during study period Exclusion: <ul style="list-style-type: none"> Enrollment in a VMAT2i clinical trial Prior treatment with VMAT2i therapy Patient deceased or lost to follow-up prior to assessment of the study outcomes
Data Source	<ul style="list-style-type: none"> Electronic health record Specialty pharmacy management system Pharmacy claims
Outcomes	<ul style="list-style-type: none"> Time to discontinuation of VMAT2i therapy, if applicable Reason for VMAT2i discontinuation, if applicable Rate of adverse events resulting from VMAT2i regimen
Analysis	<ul style="list-style-type: none"> Descriptive statistics

REFERENCES

- Koch J, Shi WX, Dashtipour K. VMAT2 inhibitors for the treatment of hyperkinetic movement disorders. *Pharmacol Ther.* 2020;212:107580. doi:10.1016/j.pharmthera.2020.107580
- Jankovic J, Jimenez-Shahed J, Budman C, et al. Deutetrabenazine in Tics Associated with Tourette Syndrome. *Tremor Other Hyperkinet Mov (N Y).* 2016;6:422.
- Niemann N, Jankovic J. Real-World Experience With VMAT2 Inhibitors. *Clin Neuropharmacol.* 2019;42(2):37-41.

RESULTS

Table 1. Patient Demographics (N = 14)


Characteristic	n (%)
Median Age, years (IQR)	37 (32 – 44)
Gender: Male	8 (57)
Race: White	14 (100)
Diagnosis and ICD-10 Code	
Tourette's disorder (F95.2)	4 (29)
Unspecified tic disorder (F95.9)	3 (21)
Both F95.2 and F95.9	7 (50)
Comorbid Conditions	
Attention-deficit hyperactivity disorder (ADHD)	2 (14)
Anxiety	7 (50)
Depression	7 (50)
Obsessive-compulsive disorder (OCD)	7 (50)
None of the above	4 (29)

Table 2. Rate of Adverse Events

Adverse Event	n (%)
Drowsiness/sedation	6 (21)
Fatigue	4 (14)
Musculoskeletal	4 (14)
Depression	3 (11)
Gastrointestinal	3 (11)
Other psychiatric*	2 (7)
Worsening movements	2 (7)
Anticholinergic*	1 (4)
Hyperprolactinemia	1 (4)
Headache	1 (4)
Sleep disturbances	1 (4)


*: anxiety, perseveration; +: dry mouth and urinary retention

Figure 2: VMAT2i Therapy Changes, Discontinuations, and Adverse Events



- 5 (36%) patients were persistent during the full study period
- Reported adverse events rates were lower for patients with higher persistence
- Treatment lapse occurred due to insurance issues for 1 (7%) patient and desire to delay switching for 1 (7%) patient during the study period

Figure 1. Intersection of Prior Medication Trials



‡ = Two patients had no documented medication trials prior to VMAT2i therapy initiation

- A variety of prior treatment option combinations was seen among patients
- There was a median of 3 prior medication trials (Interquartile Range: 2 - 4) prior to VMAT2i initiation
- Two patients did not receive any recorded prior medications before starting a VMAT2i

CONCLUSIONS

- Half of patients (n=7, 50%) discontinued VMAT2i therapy prior to the end of the 12-month follow-up period, which was higher than the discontinuation rate of prior VMAT2i studies (ranging from 8% to 55%)
- Patient characteristics indicate a high treatment resistance with a median of 3 prior medications and multiple comorbid conditions for a majority of the study population
- Reported adverse events were the main driver for patient discontinuation with most events being reported within 100 days of VMAT2i initiation
- Further studies exploring persistence rates of VMAT2i therapy in the setting of common comorbid conditions are needed